Clinical Trial Update: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This entry notes an ongoing Phase I/II clinical trial, currently recruiting, evaluating BG1805 injection for relapsed or refractory acute myeloid leukemia, cond…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BG1805 Injection

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: RECRUITING